Finally, event-based models triggered at the moment of diabetes progression (e.g., insulin initiation, step-up to combination oral therapy, or sharp HbA1c rise) within integrated health systems stratify 12–36-month PDAC risk with c-index range of 0.70–0.78, supporting a dynamic, event-based screening strategy [65]. The gene discussed is INS; the disease is diabetes mellitus.